{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:59Z","timestamp":1790916839626,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":144,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101263","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:43:13Z","timestamp":1779781393000},"page":"101263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study"],"prefix":"10.1016","volume":"48","author":[{"given":"Yan-Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Qing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Chuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6157-4006","authenticated-orcid":false,"given":"Yun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ctarc.2026.101263_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10068","key":"10.1016\/j.ctarc.2026.101263_bib0002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101263_bib0003","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/cells13100853","article-title":"Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy","volume":"13","author":"Rocchi","year":"2024","journal-title":"Cells"},{"issue":"5997","key":"10.1016\/j.ctarc.2026.101263_bib0004","first-page":"1345","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science (1979)"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101263_bib0005","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101263_bib0006","article-title":"A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and \u201con-demand\u201d plerixafor in multiple myeloma patients treated with novel agents","volume":"16","author":"Mina","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101263_bib0007","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/bmt.2009.370","article-title":"Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma","volume":"45","author":"Gertz","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101263_bib0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101263_bib0009","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101263_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.410","article-title":"Improving stem cell mobilization strategies: future directions","volume":"43","author":"Bensinger","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101263_bib0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101263_bib0012","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2003.1.419","article-title":"Stem cell mobilization","volume":"2003","author":"Cottler-Fox","year":"2003","journal-title":"Hematology"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101263_bib0013","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101263_bib0014","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101263_bib0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001813-200304000-00002","article-title":"Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients","volume":"14","author":"Molineux","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101263_bib0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","article-title":"Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor","volume":"29","author":"Arvedson","year":"2015","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101263_bib0017","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00277-019-03800-0","article-title":"Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma","volume":"99","author":"Ding","year":"2020","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101263_bib0018","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1537-2995.2006.00699.x","article-title":"A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma","volume":"46","author":"Bruns","year":"2006","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101263_bib0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101263_bib0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International society of hematotherapy and graft engineering","volume":"5","author":"Sutherland","year":"1996","journal-title":"J. Hematother."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101263_bib0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101263_bib0022","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/fon-2018-0814","article-title":"Chemotherapy-induced neutropenia\/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study","volume":"15","author":"Ludwig","year":"2019","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101263_bib0023","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00277-023-05604-9","article-title":"Efficacy and safety of biosimilar peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar filgrastim, lenograstim, and originator peg-filgrastim","volume":"103","author":"Marchesi","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101263_bib0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12288-018-0966-5","article-title":"Pegfilgrastim: more cost effective and equally efficacious option as compared to filgrastim in autologous stem cell transplant","volume":"35","author":"Sheth","year":"2019","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101263_bib0025","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/j.1537-2995.2012.03579.x","article-title":"Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis","volume":"52","author":"Costa","year":"2012","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101263_bib0026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00277-019-03901-w","article-title":"A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant","volume":"99","author":"Martino","year":"2020","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101263_bib0027","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1517\/14712598.5.12.1635","article-title":"Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action","volume":"5","author":"Lyman","year":"2005","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101263_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-98453-7","article-title":"Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma","volume":"15","author":"Goto","year":"2025","journal-title":"Sci. Rep."},{"issue":"51","key":"10.1016\/j.ctarc.2026.101263_bib0029","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028218","article-title":"Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China: a systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101263_bib0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00277-023-05228-z","article-title":"Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation","volume":"102","author":"Martino","year":"2023","journal-title":"Ann. Hematol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:00Z","timestamp":1790913660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":30,"alternative-id":["S2468294226001747"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101263","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101263"}}